The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients

TY - JOUR

T1 - The management and survival of patients with advanced germ-cell tumours

T2 - improving outcome in intermediate and poor prognosis patients

AU - Bhala, N

AU - Coleman, J M

AU - Radstone, C R

AU - Horsman, J M

AU - George, Jacob

AU - Hancock, B W

AU - Hatton, M Q

AU - Coleman, R E

PY - 2004

Y1 - 2004

N2 - The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.

AB - The survival of germ-cell tumours (GCT) was transformed after the introduction of cisplatin-based therapy. Previous trials have indicated BEP (bleomycin, etoposide and cisplatin) as the optimum treatment, although some centres including our own advocate the use of the alternating regimen POMB-ACE (cisplatin, vincristine, methotrexate, bleomycin and dactinomycin, cyclophosphamide and etoposide) for men with intermediate or poor prognosis disease. We analysed the survival and management of GCT patients treated at a specialist cancer centre in relation to internationally recognised prognostic groupings.

U2 - 10.1016/S0936-6555(03)00166-3

DO - 10.1016/S0936-6555(03)00166-3

M3 - Article

C2 - 14768754

SN - 0936-6555

VL - 16

SP - 40

EP - 47

JO - Clinical Oncology

JF - Clinical Oncology

IS - 1

ER -